cln-081,mobocertinib
cullinan oncology,otsuka,takeda
['sclc', 'mobocertinib', 'nsclc', 'cln-081 ']
#asco22 dr. presents exciting phase 1/2a on cln-081 in #egfr exon 20 insertion nsclc. we do have approved agents here (amivantamab, mobocertinib) but certainly room for more. cln-081 is an irreversible oral egfr kinase inhibitor with selectivity for #egfrex20. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him